Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zotemtegrast - Eli Lilly and Company

Next Previous
Drug Profile

Zotemtegrast - Eli Lilly and Company

Alternative Names: LY-4268989; MORF-057; MR-beta7

Latest Information Update: 04 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard Medical School; Morphic Therapeutic
  • Developer Eli Lilly and Company
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Integrin alpha4beta7 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis

Most Recent Events

  • 26 Mar 2026 Phase-II clinical trials in Ulcerative colitis (Treatment-resistant) in USA (PO) (NCT07415044)
  • 17 Feb 2026 Eli Lilly and Company plans a phase II (EMERALD-3) trial for Ulcerative colitis (Treatment- resistant) in Argentina, Brazil, Canada, China, Croatia, Czech Republic, France, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Poland, Puerto Rico, Slovakia, South Korea, Taiwan, Turkey, Ukraine and USA (PO) in April 2026 (NCT07415044)
  • 17 Feb 2026 Eli Lilly and Company completes a phase I pharmacokinetics and drug-drug interaction trial (In volunteers) in USA (PO, Tablet/Capsule) (NCT06964776)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top